RWA Wealth Partners LLC Boosts Position in Novo Nordisk A/S (NYSE:NVO)

RWA Wealth Partners LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 366.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 92,806 shares of the company's stock after purchasing an additional 72,924 shares during the quarter. RWA Wealth Partners LLC's holdings in Novo Nordisk A/S were worth $9,601,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. International Assets Investment Management LLC increased its position in shares of Novo Nordisk A/S by 133.2% in the third quarter. International Assets Investment Management LLC now owns 7,837 shares of the company's stock valued at $719,000 after buying an additional 4,476 shares in the last quarter. AE Wealth Management LLC increased its position in Novo Nordisk A/S by 142.8% during the 3rd quarter. AE Wealth Management LLC now owns 26,888 shares of the company's stock worth $2,445,000 after purchasing an additional 15,812 shares in the last quarter. AdvisorNet Financial Inc increased its position in Novo Nordisk A/S by 54.5% during the 3rd quarter. AdvisorNet Financial Inc now owns 2,758 shares of the company's stock worth $251,000 after purchasing an additional 973 shares in the last quarter. IFP Advisors Inc increased its position in Novo Nordisk A/S by 61.6% during the 3rd quarter. IFP Advisors Inc now owns 4,244 shares of the company's stock worth $386,000 after purchasing an additional 1,618 shares in the last quarter. Finally, Arkadios Wealth Advisors increased its position in Novo Nordisk A/S by 99.5% during the 3rd quarter. Arkadios Wealth Advisors now owns 3,671 shares of the company's stock worth $334,000 after purchasing an additional 1,831 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 2.1 %

Novo Nordisk A/S stock traded up $2.52 during midday trading on Monday, hitting $125.23. 3,797,307 shares of the company were exchanged, compared to its average volume of 4,871,253. The company's fifty day moving average price is $126.39 and its 200-day moving average price is $111.03. The company has a market cap of $561.97 billion, a PE ratio of 46.14, a price-to-earnings-growth ratio of 2.05 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The company had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. On average, research analysts predict that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were issued a $0.664 dividend. This represents a dividend yield of 0.9%. This is an increase from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S's payout ratio is 49.17%.

Wall Street Analyst Weigh In

NVO has been the subject of a number of recent research reports. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an "outperform" rating and a $163.00 price objective for the company. UBS Group assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a "neutral" rating on the stock. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an "overweight" rating and a $120.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.